Literature DB >> 8675149

Expression of immunoreactive matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in human normal livers and primary liver tumors.

T Terada1, Y Okada, Y Nakanuma.   

Abstract

Matrix metalloproteinases (MMPs) play an important role in cancer cell invasion by degrading extracellular matrix proteins. However, little is known about the in situ expression of MMP in human normal livers and primary liver tumors. In this study, we therefore examined the in situ expression of immunoreactive MMP and tissue inhibitors of MMP (TIMP) in 10 normal livers, 11 surgically resected intrahepatic cholangiocarcinomas (CCs), and 6 surgically resected hepatocellular carcinomas (HCCs). In normal livers, MMP and TIMP were infrequently and faintly expressed in bile ducts, but were not expressed in hepatocytes. In the 11 CCs, MMP-1, MMP-2, MMP3, MMP-9, TIMP-1, and TIMP-2 were expressed in tumor cells and/or tumor stroma in 11 (100%), 5 (45%), 8 (73%), 3 (27%), 9 (82%), and 9 (82%), respectively. The expression of MMP and TIMP in tumor cells was located in the cytoplasm with a diffuse or granular pattern; that in the tumor stroma was situated in fibroblasts, leukocytes, and extracellular matrix. Their expression was stronger in CC cases with severe invasion than in CC cases with mild invasion. In contrast, MMP and TIMP were not expressed in any cases of HCC. These results show that intrahepatic bile duct cells may neoexpress or overexpress MMP and TIMP after malignant transformation but that hepatocytes do not, and suggest that MMP and TIMP play an important role in CC cell invasion by degrading extracellular matrix proteins.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8675149     DOI: 10.1053/jhep.1996.v23.pm0008675149

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  21 in total

Review 1.  The role of cancer-associated myofibroblasts in intrahepatic cholangiocarcinoma.

Authors:  Alphonse E Sirica
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-11-29       Impact factor: 46.802

Review 2.  Matrix metalloproteinases. Novel targets for directed cancer therapy.

Authors:  A E Yu; R E Hewitt; E W Connor; W G Stetler-Stevenson
Journal:  Drugs Aging       Date:  1997-09       Impact factor: 3.923

3.  Molecular mechanisms of cholangiocarcinoma.

Authors:  Giammarco Fava
Journal:  World J Gastrointest Pathophysiol       Date:  2010-04-15

4.  High expression of matrix metalloproteinase-9 indicates poor prognosis in human hilar cholangiocarcinoma.

Authors:  Qi Sun; Chuanzong Zhao; Leizhou Xia; Zhaobin He; Zhihua Lu; Chuan Liu; Ming Jia; Jiayong Wang; Jun Niu
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

5.  Proteinase-activated receptor 2 (PAR(2)) in cholangiocarcinoma (CCA) cells: effects on signaling and cellular level.

Authors:  Roland Kaufmann; Alexander Hascher; Franziska Mussbach; Petra Henklein; Kathrin Katenkamp; Martin Westermann; Utz Settmacher
Journal:  Histochem Cell Biol       Date:  2012-08-15       Impact factor: 4.304

6.  Cyclooxygenase-2 is involved in the up-regulation of matrix metalloproteinase-9 in cholangiocarcinoma induced by tumor necrosis factor-alpha.

Authors:  Keita Itatsu; Motoko Sasaki; Junpei Yamaguchi; Shusaku Ohira; Akira Ishikawa; Hiroko Ikeda; Yasunori Sato; Kenichi Harada; Yoh Zen; Hiroshi Sato; Tetsuo Ohta; Masato Nagino; Yuji Nimura; Yasuni Nakanuma
Journal:  Am J Pathol       Date:  2009-02-13       Impact factor: 4.307

Review 7.  Reactivation of the insulin-like growth factor-II signaling pathway in human hepatocellular carcinoma.

Authors:  Kai Breuhahn; Peter Schirmacher
Journal:  World J Gastroenterol       Date:  2008-03-21       Impact factor: 5.742

8.  A matrix metalloproteinase inhibitor to treat unresectable cholangiocarcinoma.

Authors:  J J French; M J Midwinter; M K Bennett; D M Manas; R M Charnley
Journal:  HPB (Oxford)       Date:  2005       Impact factor: 3.647

9.  Evidence for altered hepatic matrix degradation in genetic haemochromatosis.

Authors:  D K George; G A Ramm; L W Powell; L M Fletcher; N I Walker; L L Cowley; D H Crawford
Journal:  Gut       Date:  1998-05       Impact factor: 23.059

Review 10.  Pathogenesis, diagnosis, and management of cholangiocarcinoma.

Authors:  Sumera Rizvi; Gregory J Gores
Journal:  Gastroenterology       Date:  2013-10-15       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.